Major advances in the treatment of lung cancer, specifically targeted therapies and immunotherapies, have demonstrated a survival benefit in clinical trials. To measure the effects of these advances at the population level, researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, conducted an analysis of the US Surveillance, Epidemiology, and […]
Read more